Rob Black's Healthcare Market Roundup For March 25 (AHG, DNA, FRX, LH, PG) 1 comment
-
Font Size:
-
Print
- TweetThis
Forest Labs will incur significant milestone and R&D expense in the coming year. The company expects 10-11% sequential increase in Lexapro sales. The company also expects Namenda sales to be up 22% sequentially.
Procter & Gamble (PG) was upgraded to Strong Buy at Buckingham.
Apria Healthcare Group (AHG) said profit fell to $16.1 million from $25.2 million a year ago. Revenue declined to $368.1 million from $371.9 million in last year's first quarter. The respiratory therapy provider said results were hurt by a drop in Medicare reimbursements.
Laboratory Corporation of America (LH) reported earnings of $101.9 million up from $96.6 million in the year-earlier period. Revenue rose to $878.5 million from last year's $799.1 million. Looking ahead, the drug testing technologies company still expects revenue growth of 6.5% to 7.5%.
RBC expects positive Phase III data for Genentech Inc’s (DNA) Avastin in kidney cancer and pancreatic cancer in 2006. They say Phase II results for an Avastin/Tarceva combination in lung cancer will be presented at ASCO in June, which could signal potential positive data from an ongoing Phase III trial in this setting.
Related Articles
|























This article has 1 comment: